Schneyer Mark C.
Known title: Chief Financial OfficerCIK: 0001899977
Associated companies
Transaction History
| ACAD | ▲ Buy | Option Exercise | 14,292 | $255K | 8/6/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,000 | $145K | 8/6/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 9,292 | $273K | 8/6/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,849 | $104K | 8/5/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,849 | $170K | 8/5/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,506 | $76K | 5/4/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,815 | — | 5/1/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,709 | $60K | 4/7/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,276 | — | 4/5/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,171 | $69K | 3/26/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 37 | $804 | 3/26/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 4,177 | $90K | 3/25/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,178 | — | 3/25/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 8,138 | — | 3/24/2026 | View on chart |
| ACAD | ▼ Sell | Open Market | 10,262 | $243K | 11/18/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,913 | — | 11/17/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,913 | — | 11/17/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,498 | $83K | 9/15/2025 | View on chart |
| ACAD | ▲ Buy | Grant | 6,815 | $0 | 9/12/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 22,000 | $554K | 8/18/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,000 | $50K | 5/16/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,498 | $51K | 5/2/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,815 | — | 5/1/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,708 | $40K | 4/8/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,275 | — | 4/5/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,171 | $54K | 3/26/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,178 | — | 3/25/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 773 | $15K | 2/24/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,353 | — | 2/23/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 10,259 | $172K | 11/19/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,913 | — | 11/17/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,913 | — | 11/17/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 9,733 | $149K | 8/19/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 13,629 | $0 | 8/16/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 5,275 | $0 | 8/16/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 975 | $14K | 6/10/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,893 | — | 6/8/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,503 | $59K | 5/2/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,814 | — | 5/1/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,716 | $49K | 4/8/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,275 | — | 4/5/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,434 | $97K | 3/27/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 10,550 | $0 | 3/25/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 772 | $19K | 2/26/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,353 | — | 2/23/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,108 | $116K | 11/20/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 4,956 | — | 11/17/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 4,956 | — | 11/17/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 10,000 | $290K | 8/21/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,893 | $0 | 6/8/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 974 | $24K | 6/8/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 14,869 | — | 5/17/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 15,310 | $344K | 5/17/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 14,869 | — | 5/17/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,916 | $35K | 4/6/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,275 | — | 4/5/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 577 | $11K | 2/24/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,353 | — | 2/23/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 653 | $12K | 6/9/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,893 | $0 | 6/8/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,352 | $0 | 2/23/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 553 | $13K | 2/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.